id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-E-2337-0008,FDA,FDA-2020-E-2337,Letter from U.S. Patent and Trademark Office to CDER,Other,Letter(s),2024-03-25T04:00:00Z,2024,3,2024-03-25T04:00:00Z,,2024-03-25T22:56:01Z,,0,0,0900006486469ce5
FDA-2020-E-2337-0007,FDA,FDA-2020-E-2337,Letter from FDA CDER to U.S.  Patent and Trademark Office,Other,Letter(s),2024-01-25T05:00:00Z,2024,1,2024-01-25T05:00:00Z,,2024-01-25T14:48:00Z,,0,0,09000064863c1fa1
FDA-2020-E-2337-0006,FDA,FDA-2020-E-2337,Determination of Regulatory Review Period for Purposes of Patent Extension; ROZLYTREK INJECTION; Correction,Notice,Correction,2023-11-17T05:00:00Z,2023,11,2023-11-17T05:00:00Z,,2023-11-17T21:10:48Z,2023-25489,0,0,090000648628d12c
FDA-2020-E-2337-0005,FDA,FDA-2020-E-2337,Determination of Regulatory Review Period for Purposes of Patent Extension; ROZLYTREK INJECTION,Notice,Determinations,2022-07-08T04:00:00Z,2022,7,2022-07-08T04:00:00Z,2022-09-07T03:59:59Z,2023-11-17T21:10:32Z,2022-14546,0,0,09000064851b553a
FDA-2020-E-2337-0004,FDA,FDA-2020-E-2337,Letter from FDA CDER to U S Patent and Trademark Office,Other,Letter(s),2022-06-14T04:00:00Z,2022,6,2022-06-14T04:00:00Z,,2022-06-14T16:52:10Z,,0,0,0900006485162dfd
FDA-2020-E-2337-0003,FDA,FDA-2020-E-2337,Patent Term Extension Letter from FDA CDER to Honorable Drew Hirshfeld,Other,Extension of Time,2021-03-01T05:00:00Z,2021,3,2021-03-01T05:00:00Z,,2021-03-01T17:57:04Z,,0,0,0900006484a57db5
FDA-2020-E-2337-0001,FDA,FDA-2020-E-2337,Letter from U S Patent and Trademark Office,Other,Letter(s),2020-12-23T05:00:00Z,2020,12,2020-12-23T05:00:00Z,,2020-12-23T13:31:44Z,,0,0,09000064849c11a1
FDA-2020-E-2337-0002,FDA,FDA-2020-E-2337,"Patent Term Extension Application for ROZLYTREK® Patent No 9,085,565",Other,Application,2020-12-23T05:00:00Z,2020,12,2020-12-23T05:00:00Z,,2020-12-23T13:32:55Z,,0,0,09000064849c11a2